Trial of Pembrolizumab in Cancer of Unknown Primary

NCT03752333 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Cancer of Unknown Primary Site

Interventions

DRUG: Pembrolizumab

Sponsor

Imperial College London

Collaborators

[object Object]